Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Coverage for sleep apnea Zepbound's second FDA indication gets its own section of cnf_684: "Obstructive Sleep Apnea, Moderate to Severe, in a Patient with Obesity" approved for 1 year when you're 18 or older with a baseline BMI of 30 or higher and a sleep study showing an apnea-hypopnea index of 15 or more events per hour
Individuals interested in trial participation may wish to consult ClinicalTrials.gov or speak with their GP or specialist
10.1038/s41586-019-1411-0 34 ChaY
Long-term follow-up studies extending beyond the initial trial periods confirmed that weight loss benefits persisted with continued treatment over 2-3 years
Always happy with the results
Most patients find they naturally eat smaller portions and make better food decisions as their cravings decrease and their appetite adjusts
US$ 28.44
US$ 24.05
US$ 28.17
US$ 29.03
